Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 01, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will present a corporate overview and host investor meetings during the Jefferies Healthcare Conference, held in New York City, from June 6 - 9, 2017.
Matt Kapusta, chief executive officer, will present on Friday, June 9, 2017 at 8:00 am EDT. The live webcast of the presentation can be accessed through the link displayed in the Investor Section of uniQure website at http://uniqure.com/investors-newsroom/events-presentations.php. A replay of the webcast will be available within 24 hours following the event, and will remain available for at least two weeks.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com
uniQure Contacts: Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 [email protected] Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 [email protected] Eva M. Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 [email protected]
